The pharmaceutical intermediates market is a dynamic and critical sector that fuels innovation in drug discovery and development. Within this landscape, specialized compounds like BB-22 (CAS 1400742-42-8) play a vital role. This article examines the significance of BB-22, its properties, and its place within the broader market for pharmaceutical materials, offering insights for researchers and procurement specialists.

BB-22, chemically known as Quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate, is a compound frequently sought after for its utility as a research chemical and an intermediate in complex organic synthesis. Its precise molecular structure (C25H24N2O2) and molecular weight (384.47026) make it a valuable building block for new drug candidates. Professionals in the field often use search terms like 'buy BB-22,' 'BB-22 pharmaceutical intermediate China,' and 'CAS 1400742-42-8 supplier' to locate reliable sources for this compound.

The market for pharmaceutical intermediates is characterized by a strong demand for high purity and consistent quality. For BB-22, ensuring a purity level above 99.7% is essential for its intended applications in sensitive research environments. The availability of this compound from manufacturers and suppliers, particularly those in China, reflects the globalized nature of the chemical industry. Key considerations for buyers include not only the price but also the supplier's track record, quality control measures, and logistical capabilities.

Companies looking to procure BB-22 benefit from understanding its key characteristics, such as its typical appearance as a white powder and its solubility profiles in solvents like DMF or DMSO. These details are crucial for effective laboratory use and process optimization. Furthermore, reliable suppliers often provide comprehensive technical support, including certificates of analysis, which are indispensable for regulatory compliance and internal quality assurance.

As the pharmaceutical industry continues to evolve, the demand for specialized intermediates like BB-22 is expected to remain strong. By identifying and partnering with reputable manufacturers and suppliers, research institutions and pharmaceutical companies can ensure they have access to the high-quality materials necessary to drive innovation and bring new therapies to market. A strategic approach to sourcing BB-22 is, therefore, an investment in the success of future pharmaceutical advancements.